Boca Raton Regional Hospital | Lynn Clinical Research Center

Research site

(Unclaimed)

Location

701 NW 13th Street, Boca Raton, Florida, United States of America

Site insights

Top conditions

Top treatments

Bevacizumab

Temozolomide

Abemaciclib

Cisplatin

Tamoxifen Citrate

Gemcitabine

Paclitaxel

Letrozole

Exemestane

Bicalutamide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 90 total trials

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and earl...

Enrolling

Solid Tumor

Pleural Mesothelioma

Drug: MDNA11

Drug: Pembrolizumab (KEYTRUDA®)

A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma

This is a multi-center clinical study enrolling up to 86 participants. The primary objectives are to determine the objective response rate (ORR) esta...

Enrolling

Recurrent Squamous Cell Carcinoma

Device: DaRT seeds

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients with CtDNA-positive, Resected Stage II (high Risk) and Stage III Colorectal Cancer

This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulati...

Enrolling

Colorectal Cancer Stage III

Colorectal Cancer Stage II

Drug: RO7198457 intravenous (IV)

Other: Observational group (no intervention)

A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER)

The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.

Active, not recruiting

Non Small Cell Lung Cancer

Drug: Erlotinib

Drug: Abemaciclib

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Enrolling

Ischemic Stroke; Ischemic Attack, Transient

Drug: Placebo

Drug: Milvexian

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2)

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV)...

Active, not recruiting

Urinary Bladder Neoplasms

Drug: Cisplatin

Radiation: Hypo-fractioned radiation therapy

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetax...

Enrolling

Prostate Cancer

Drug: Radium-223

Drug: Docetaxel 60 mg/m2

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)

This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclo...

Enrolling

Refractory Diffuse Large B-cell Lymphoma

Relapsed Diffuse Large B-cell Lymphoma

Drug: DPX-Survivac

Drug: Pembrolizumab

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEIII)

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to ful...

Enrolling

Metastatic Breast Cancer

Drug: Lasofoxifene in combination with abemaciclib

Drug: Fulvestrant in combination with abemaciclib

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several...

Enrolling

KRAS G12C Mutation

PI3K Gene Mutation

Drug: PI3K Inhibitor paxalisib

Drug: Entrectinib

Post-Approval Study of the TREO Abdominal Stent-Graft System (TREO PAS)

The purpose of this study is to determine the long-term performance of the TREO Abdominal Stent-Graft as a treatment for patients with Infrarenal Abd...

Enrolling

Abdominal Aortic Aneurysm

Device: TREO Abdominal Stent-Graft System

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSC...

Active, not recruiting

Non-small Cell Lung Cancer

Drug: DS-1062a

Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)

This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with...

Active, not recruiting

Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia

Drug: Pirtobrutinib

Drug: Bendamustine

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02)

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo comb...

Enrolling

Carcinoma, Non-Small-Cell Lung

Drug: Olomorasib

Drug: Placebo

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1)

Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is in...

Active, not recruiting

Follicular Lymphoma (FL)

Drug: Lenalidomide

Drug: Rituximab

Locations recently updated

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and...

Enrolling

Cancer

Drug: Darolutamide (Nubeqa, BAY1841788)

T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in pa...

Enrolling

Anatomic Stage III Breast Cancer AJCC V8

Anatomic Stage IIIA Breast Cancer AJCC V8

Biological: Trastuzumab Emtansine

Other: Quality-of-Life Assessment

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with me...

Enrolling

Recurrent Meningioma

NF2 Gene Mutation

Drug: Vismodegib

Drug: Abemaciclib